The expanding role of angiotensin receptor blockers in the management of the elderly hypertensive

Current Medical Research and Opinion

Volumn 19, Issue 5, 2003, Pages 452-455

  McInnes, Gordon T ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

Angiotensin receptor blockers; Candesartan; Cognitive decline; Elderly; Hypertension; Stroke

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT;

AGE; AGING; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; COMORBIDITY; CONFERENCE PAPER; DEVELOPING COUNTRY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG TOLERABILITY; ELDERLY CARE; HUMAN; HYPERTENSION; RISK FACTOR; STROKE; TREATMENT PLANNING;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CEREBROVASCULAR ACCIDENT; COGNITION DISORDERS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; HYPERTENSION; RECEPTORS, ANGIOTENSIN;

EID: 0043235895     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125001992     Document Type: Conference Paper

References (19)

1. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-64
2. Dahlof B, Lindholm LH, Hansson L, et al. Mortality and morbidity in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338:1281-5
3. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992;304:405-12
4. Hansson L, Lindholm LH, Ekbom T, et al. for the STOP-Hypertension-2 study group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6
5. Belcher G, Hubner R, George M, Elmfeldt D, Lunde H. Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. J Hum Hypertens 1997;11(Suppl 2):S85-9
6. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998;20(4):671-81
7. Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther 2001;23(12):1999-2010
8. Neldam S, Forsen B. Multicentre Study Group. Antihypertensive treatment in elderly patients aged 75 years or over: a 24 week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide. Drugs Aging 2001;18:225-32
9. McInnes GT, O'Kane KP, Jonker J, et al. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J Hum Hypertens 1997;11(Suppl 2):S75-S80
10. Lewis EJ, Hunsicker LG, Clarke WR, et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345(12):851-60
11. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321(7274):1440-4
12. Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345(23):1667-75
13. Granger CB, Bart BA, Held P, et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J 2000;139(4):609-17
14. Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003
15. Insua JT, Sacks HS, Lau T-S, et al. Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med 1994;121:355-62
16. Schrader J, Luders S, Kulschewski A, et al. ACCESS Study: Acute Candesartan Cilexetil Evaluation in Stroke Survivors. Double-blind randomised comparison of candesartan cilexetil and placebo in the control of blood pressure following stroke. 11th Congress of the European Hypertension Society. Germany 2001; Oral presentation
17. Fagard RH, Staessen JA. Treatment of isolated systolic hypertension in the elderly: the Syst-Eur trial. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Clin Exp Hypertens 1999;21:491-7
18. Lithell H, Hansson L, Skoog I, et al., for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86
19. Lacourcière Y, Asmar R for the Candesartan/Losartan study investigators. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose., in truly hypertensive patients: a placebo-controlled, forced titration study. Am J Hypertens 1999;12:1181-7